Tryptamine Microdose Compositions for Neurite Outgrowth

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for neurogenic and nootropic compositions that can enhance neuronal disorders and cognitive functions by combining sub-hallucinogenic 'microdoses' of tryptamines, phenethylamines, or amphetamines with other neurogenic compounds such as erinacines and hericenones, cannabinoids, and other natural products to treat a variety of neuronal disorders and enhance cognition and sensory motor neuron functioning.

Innovation Solution

A composition comprising norpsilocin or its salts combined with erinacines and hericenones from Hericium mushrooms, cannabinoids from Cannabis species, and optionally phenethylamines and amphetamines, along with pharmaceutically acceptable excipients, is administered to promote neurite outgrowth and treat conditions like serotonin receptor disorders, neurodegeneration, and psychiatric disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If tryptamines, phenethylamines, or amphetamines are used to treat neuronal disorders and enhance cognition, then cognitive function and neuronal health are improved, but harmful psychological effects and addiction potential increase

Engineering Contradiction:

Improveneural health and cognitive functionVSAvoidpsychological harm and addiction potential

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by using sub-hallucinogenic microdoses of tryptamines, phenethylamines, or amphetamines instead of conventional therapeutic doses. This dosage parameter modification reduces harmful psychological effects and addiction potential while maintaining beneficial neural health and cognitive enhancement effects.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent combines multiple compounds (tryptamines, phenethylamines, amphetamines, erinacines, hericenones, cannabinoids, and other natural products) into composite compositions that work synergistically. This composite approach enhances cognitive function and neuronal health while the specific combination and dosing reduce harmful effects compared to single-agent therapy.

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional doses of psychedelics are used to promote neurogenesis and treat psychiatric disorders, then therapeutic effects are enhanced, but harmful psychological effects and legal issues increase

Engineering Contradiction:

Improvetherapeutic effectVSAvoidpsychological harm and legal status

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent fundamentally changes the dosage parameter from conventional therapeutic doses to sub-hallucinogenic microdoses. This parameter change maintains therapeutic effects such as neurogenesis promotion and psychiatric disorder treatment while eliminating harmful psychological effects and reducing legal complications associated with psychedelic substances.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies partial action by using sub-hallucinogenic doses that produce therapeutic effects without the full hallucinogenic experience. This partial approach achieves the desired therapeutic outcome (neurogenesis, mood improvement) while avoiding the harmful full psychedelic effect and associated legal issues.

Inventive Principle:

Principle #16Partial or excessive action

3Reliability

If multiple compounds are combined in compositions to enhance neuronal growth and cognitive function, then therapeutic effectiveness is improved, but composition complexity and manufacturing difficulty increase

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidcomposition complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges multiple compounds (tryptamines, phenethylamines, amphetamines, erinacines, hericenones, cannabinoids, and other natural products) into unified compositions that work synergistically. This combining approach enhances therapeutic effectiveness for neuronal growth and cognitive function while the formulations are designed to manage complexity through standardized preparation methods.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent creates multi-functional compositions that can treat various conditions (neuronal disorders, cognitive impairment, psychiatric disorders) and promote multiple outcomes (neurite outgrowth, neurogenesis, mood improvement) simultaneously. This universal approach improves therapeutic effectiveness across different indications while the compositions are formulated to handle the complexity through versatile design.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively enhances neurite outgrowth and treats conditions such as serotonin receptor disorders, neurodegeneration, and psychiatric disorders by modulating 5-HT2A and 5-HT2C receptors, promoting neuronal regeneration and cognitive enhancement.

Implementation Method 1

Methodology Applied

Scientific EffectReceptor modulation:

Data Source

PatentUS20260048048A1Tryptamine compositions for enhancing neurite outgrowth

Publication Date: 2026.02.19 TURTLE BEAR HLDG LLC

AI summary

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients. In another aspect, tryptamine compositions described herein enhance neuroplasticity by promoting neuronal branching through the formation of neurites (i.e., neurite outgrowth) and neurite elongation (i.e., increasing neurite length).